Cancer News

FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia (01/14/2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). ABOUT CHRONIC MYELOGENOUS LEUKEMIA (CML) Chronic myelogenous leukemia (CML) is a rare blood cancer, which begins in the bone marrow, …

Continue reading "FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia"

Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia (06/14/2017)

In 2002, the FDA approved the drug Gleevec (imatinib) as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended the lives of patients with the condition and, in many ways, ushered in the era of molecularly-targeted treatments against cancer. …

Continue reading "Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia"

Have a Question about Chronic Myeloid Leukemia? Join us on May 25th! (05/02/2017)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Luskin CancerConnect announces the opportunity to engage with leukemia expert, Marlise Luskin, MD, MSCE. On May 25th, 2017, Dr. Luskin will answer your pre-submitted questions about chronic myeloid leukemia (CML) on CancerConnect. CancerConnect is an online support community for individuals affected by cancer. Dr. Luskin …

Continue reading "Have a Question about Chronic Myeloid Leukemia? Join us on May 25th!"

FDA Grants Iclusig® Expanded Approval for CML (12/14/2016)

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are not eligible for treatment with another tyrosine kinase inhibitor. The approval indication also includes adults with T3151-positive CML and T3151-positive … Continue reading "FDA Grants Iclusig® Expanded Approval for CML"